|
CA3115103A1
|
|
Pi3k inhibitors and uses thereof
|
|
US2016333014A1
|
|
Small-molecule Hsp90 inhibitors
|
|
AU2015203675A1
|
|
Triterpene saponins, methods of synthesis, and uses thereof
|
|
AU2015255692A1
|
|
Naphthaquinone methyltransferase inhibitors and uses thereof
|
|
AU2014362297A1
|
|
SGK1 inhibitors for treatment of prostate cancer
|
|
US2016289261A1
|
|
Glucocorticoid inhibitors for treatment of prostate cancer
|
|
AU2014271331A1
|
|
Glycopeptide constructs and uses thereof
|
|
AU2014233641A1
|
|
Pyridazinones and furan-containing compounds
|
|
AU2014292918A1
|
|
Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics
|
|
AU2013361366A1
|
|
Multimodal particles, methods and uses thereof
|
|
AU2013204109A1
|
|
Purine derivatives useful as hsp90 inhibitors
|
|
AU2013205338A1
|
|
Treatment of neurodegenerative diseases through inhibition of Hsp90
|
|
AU2013203096A1
|
|
Catenae: Serosal Cancer Stem Cells
|
|
AU2013240224A1
|
|
S100A8/A9 as a diagnostic marker and a therapeutic target
|
|
AU2013222185A1
|
|
Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
|
|
AU2013207785A1
|
|
Cancer-specific suicide gene for cell-based and gene therapy
|
|
AU2012362360A1
|
|
Targeted self-assembly of functionalized carbon nanotubes on tumors
|
|
AU2012202819A1
|
|
Synthetic HLA binding peptide analogues and uses thereof
|
|
CN109498812A
|
|
HSP90 combination treatment
|
|
AU2012240077A1
|
|
Hsp90 inhibitors
|
